T A Fuchsluger1, C Hintschich, K-P Steuhl, D Meller. 1. Abteilung für Erkrankungen der vorderen Augenabschnitte des Zentrums für Augenheilkunde, Universitätsklinikum, Essen. thomas@fuchsluger.net
Abstract
PURPOSE: The aim of this study was to evaluate the role of topical interferon-alpha-2b in the adjuvant treatment of corneal and conjunctival tumors. METHOD: In this noncomparative, prospective, interventional case series, five patients with histologically proven conjunctival intraepithelial neoplasia (CIN) after primary excision and amniotic membrane transplantation were treated with interferon (IFN)-alpha-2b eye drops five times daily over a period of 6 weeks (1 million IU/ml Intron A, Schering). An in situ hybridization technique was used to detect human papillomavirus (HPV) in all specimens. Frequent follow-up was undertaken clinically and photographically for evidence of tumor recurrence. RESULTS: In the follow-up period (13.2+/-4,97 months) no clinical evidence of recurrence with only limited treatment side effects such as mild conjunctival hyperemia were recorded after 6 weeks of interferon. In one CIN specimen HPV 16/18 could be detected. CONCLUSIONS: The combination of excisional biopsy and topical interferon-alpha-2b application seems to be an effective and safe treatment for conjunctival intraepithelial neoplasias. Therefore, we prefer this combined treatment to topical interferon-alpha-2b treatment alone, more destructive approaches such as radiation and cryotherapy, or treatment with antimetabolites such as 5-fluorouracil or mitomycin C.
PURPOSE: The aim of this study was to evaluate the role of topical interferon-alpha-2b in the adjuvant treatment of corneal and conjunctival tumors. METHOD: In this noncomparative, prospective, interventional case series, five patients with histologically proven conjunctival intraepithelial neoplasia (CIN) after primary excision and amniotic membrane transplantation were treated with interferon (IFN)-alpha-2b eye drops five times daily over a period of 6 weeks (1 million IU/ml Intron A, Schering). An in situ hybridization technique was used to detect human papillomavirus (HPV) in all specimens. Frequent follow-up was undertaken clinically and photographically for evidence of tumor recurrence. RESULTS: In the follow-up period (13.2+/-4,97 months) no clinical evidence of recurrence with only limited treatment side effects such as mild conjunctival hyperemia were recorded after 6 weeks of interferon. In one CIN specimen HPV 16/18 could be detected. CONCLUSIONS: The combination of excisional biopsy and topical interferon-alpha-2b application seems to be an effective and safe treatment for conjunctival intraepithelial neoplasias. Therefore, we prefer this combined treatment to topical interferon-alpha-2b treatment alone, more destructive approaches such as radiation and cryotherapy, or treatment with antimetabolites such as 5-fluorouracil or mitomycin C.
Authors: Barry A Schechter; William J Rand; Gabriel E Velazquez; William D Williams; Lewis Starasoler Journal: Am J Ophthalmol Date: 2002-08 Impact factor: 5.258
Authors: N Toledano Fernández; S García Sáenz; D Díaz Valle; A Arteaga Sánchez; M Segura Bedmar; S Lorenzo Giménez; L Cortés Lambea Journal: Arch Soc Esp Oftalmol Date: 2003-05
Authors: L Edwards; B Berman; R P Rapini; D A Whiting; S Tyring; H T Greenway; S P Eyre; D J Tanner; E L Taylor; E Peets Journal: Arch Dermatol Date: 1992-11
Authors: Annemarie Klingenstein; Christina Samel; Elisabeth M Messmer; Aylin Garip-Kuebler; Siegfried G Priglinger; Christoph R Hintschich Journal: Br J Ophthalmol Date: 2021-03-12 Impact factor: 5.908